Electra Therapeutics raised $183 million in a Series C to advance its lead candidate ELA026 into pivotal testing for secondary hemophagocytic lymphohistiocytosis (HLH) and to push a second program toward the clinic. The financing was co‑led by Nextech and EQT Life Sciences and included strategic investors such as Sanofi. Company leadership framed the round as support for rapid clinical acceleration and the expansion of manufacturing and operational capability. Investors signaled appetite for companies targeting high‑need rare inflammatory diseases with clear mechanistic rationale.